Topical carmustine (BCNU) for patch/plaque mycosis fungoides.

Abstract

This article summarizes experience with topical carmustine (BCNU) solution in 172 patients with patch/plaque stage mycosis fungoides. At 36 months 92% of stage-T1 (less than 10% skin involvement) and 64% of stage-T2 (10% or more skin involvement) patients were either in complete or partial remission. The most frequent side effect was an erythematous reaction which was followed by a benign-type telangiectasia in some patients. No secondary skin cancers were seen. Bone marrow depression was uncommon. Topical BCNU is an effective treatment for patch/plaque stage mycosis fungoides.

• Authors: H S Zackheim
• Journal: Seminars in dermatology (Semin Dermatol) Vol. 13 Issue 3 Pg. 202-6 (Sep 1994) ISSN: 0278-145X [Print] United States
• PMID: 7986689 (Publication Type: Journal Article)

Chemical References

• Carmustine

Topics

• Administration, Topical
• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Carmustine (administration & dosage, adverse effects, therapeutic use)
• Female
• Humans
• Male
• Middle Aged
• Mycosis Fungoides (drug therapy)
• Remission Induction
• Skin Neoplasms (drug therapy)
• Survival Analysis